Third Rock-backed autoimmune biotech turns off the lights
A Third Rock Ventures biotech created to make new medicines for autoimmune and inflammatory diseases has shuttered, Endpoints News has learned.
Rheos Medicines changed its registered office address and registered agent last month to that of a Foxborough, MA accounting firm that specializes in bankruptcies, per January documents. A Third Rock spokesperson confirmed to Endpoints that Rheos wound down “late last year.”
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.